Part 25 of our Bridging the Gap Series (Summary of the webinar session held in December 2025) Editor’s note: Since this webinar, Waskyra has also received approval from the U.S. Food and Drug Administration (FDA), expanding access beyond Europe. One of the hardest challenges in cell & gene therapy (CGT) is determining how programs for ultra-rare diseases […]
View Blog
Sample inventory management is a continuous process that supports the integrity of your data and research. Yet with samples and critical reagents added over time, sprawling inventories can strain valuable time, energy, and resources. An objective inventory review, conducted by better storage management experts, can help to optimize your sample and material storage and sustain […]
View Blog
Part 24 of our Bridging the Gap Series (Summary of the webinar session held in November 2025) Access to life-saving cell and gene therapies depends not only on scientific breakthroughs but also on the systems that bring those breakthroughs to patients. Regulations, infrastructure, and collaboration across borders determine whether a therapy moves from the lab to the […]
View Blog
Part 23 of our Bridging the Gap Series (Summary of the webinar session held in October 2025) The last decade has seen a revolution in the way cell and gene therapies are developed, delivered, and accessed. What began as pioneering work in bone marrow transplantation has evolved into a global ecosystem advancing engineered cell therapies that offer […]
View Blog
Proper storage of biological assets is vital to keep your research moving forward. Yet, while you focus on research activities, it’s all too common for sample and critical reagent inventories to morph into an unorganized sprawl. The most obvious impact is time spent finding your materials of interest, but there are other consequences to sample […]
View Blog
Part 22 of our Bridging the Gap Series (Summary of the webinar session held in September 2025) Access to advanced therapies is often framed as a challenge of resources and infrastructure. But in Europe, a bold new model is reshaping how patients receive life-saving CAR T-cell therapy. Instead of relying solely on commercial manufacturing and centralized approval […]
View Blog
A Strategic Guide for U.S. Pharmaceutical Manufacturers As more pharmaceutical companies bring drug manufacturing stateside, a critical but often under-planned question arises: what happens to your product after it leaves the manufacturing floor? For products requiring strict temperature control and regulatory compliance, storage isn’t just about holding space. It’s about protecting product integrity, meeting regulatory […]
View Blog
Cell and gene therapy (CGT) manufacturing can be complex. Part of the process requires precise, contamination-free thawing across a variety of critical materials. While we often focus on thawing cryopreserved cell products, another key component in CGT workflows is the controlled thawing of viral vectors used in gene modification. Researchers of King’s College London, UK, […]
View Blog
During cell therapy process development and manufacturing, you need unwavering trust in the technologies that you use. Barkey offers multiple solutions that deliver trust in the form of precise, gentle, yet robust dry thawing for your vials, bags, and bottles. Below are 10 great reasons to incorporate a Barkey dry thawing system. 10 Reasons to […]
View Blog
Part 21 of our Bridging the Gap Series (Summary of the webinar session held in August 2025) Providing access to transformative cell and gene therapies is one of the most urgent challenges in modern healthcare. These treatments offer the possibility of curing conditions once thought untreatable—yet in the United States, only a fraction of eligible patients are […]
View Blog